Showing results (51-60 of 84) with videos related to
Sort By:
Pageof 9
Neurology(R) Neuroimmunology & Neuroinflammation|October 6, 2025
Outcomes in Patients With Immune Checkpoint Inhibitor-Related Myopathy and Prolonged Follow-UpYahel Segal, Georgios Mangioris, Michel Toledano, et al.Rheumatology (Oxford, England)|March 14, 2025
A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositisElie Naddaf, Michael P Skolka, Larry Prokop, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 10, 2021
Clinical spectrum of high-titre GAD65 antibodiesAdrian Budhram, Elia Sechi, Eoin P Flanagan, et al.Neurology|April 27, 2021
Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic PanelsShahar Shelly, John R Mills, Divyanshu Dubey, et al.Brain : a Journal of Neurology|January 17, 2025
Artificial intelligence models using F-wave responses predict amyotrophic lateral sclerosisJennifer M Martinez-Thompson, Kevin A Mazurek, Carolina Parra Cantu, et al.JAMA Neurology|September 6, 2017
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) AntibodiesJustin C Kao, Bing Liao, Svetomir N Markovic, et al.Frontiers in Neurology|March 31, 2018
Myopathy With SQSTM1 and TIA1 Variants: Clinical and Pathological FeaturesZhiyv Niu, Carly Sabine Pontifex, Sarah Berini, et al.Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
NLRP3 inflammasome activation and altered mitophagy are key pathways in inclusion body myositisElie Naddaf, Thi Kim Oanh Nguyen, Jens O Watzlawik, et al.Journal of Cachexia, Sarcopenia and Muscle|December 26, 2024
NLRP3 Inflammasome Activation and Altered Mitophagy Are Key Pathways in Inclusion Body MyositisElie Naddaf, Thi Kim Oanh Nguyen, Jens O Watzlawik, et al.Rheumatology (Oxford, England)|March 14, 2022
Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluationShahar Shelly, Grayson Beecher, Margherita Milone, et al.Pageof 9